Monalizumab
- Generic Name
- Monalizumab
- Brand Names
- -
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 1228763-95-8
- Unique Ingredient Identifier
- 3ZXZ2V0588
- Background
Monalizumab has been used in trials studying the treatment of Gynecologic Cancer, Chronic Lymphocytic Leukemia, and Squamous Cell Carcinoma of the Oral Cavity.
- Associated Conditions
- -
- Associated Therapies
- -
Testing the Safety of Adding Either Monalizumab (IPH2201) or Oleclumab (MEDI9447) to Durvalumab (MEDI4736) Plus Standard Radiation Therapy for Locally Advanced Non-small Cell Lung Cancer (NSCLC), ARCHON-1 Trial
Phase 1
Active, not recruiting
- Conditions
- Locally Advanced Lung Non-Small Cell CarcinomaLocally Recurrent Lung Non-Small Cell CarcinomaUnresectable Lung Non-Small Cell CarcinomaStage II Lung Cancer AJCC v8Stage III Lung Cancer AJCC v8
- Interventions
- Radiation: Accelerated Hypofractionated Radiation TherapyProcedure: Biospecimen CollectionProcedure: Computed TomographyBiological: DurvalumabProcedure: Magnetic Resonance Imaging of the Brain with and without ContrastBiological: MonalizumabBiological: OleclumabRadiation: Radiation Therapy
- First Posted Date
- 2019-01-14
- Last Posted Date
- 2024-12-16
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 48
- Registration Number
- NCT03801902
- Locations
- 🇺🇸
MD Anderson in The Woodlands, Conroe, Texas, United States
🇺🇸M D Anderson Cancer Center, Houston, Texas, United States
🇺🇸MD Anderson West Houston, Houston, Texas, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath